PMID- 27606888
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20231112
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Print)
IS  - 1520-7552 (Linking)
VI  - 33
IP  - 3
DP  - 2017 Mar
TI  - A global study of the unmet need for glycemic control and predictor factors among 
      patients with type 2 diabetes mellitus who have achieved optimal fasting plasma 
      glucose control on basal insulin.
LID - 10.1002/dmrr.2858 [doi]
LID - e2858
AB  - BACKGROUND: This study used data from different sources to identify the extent of 
      the unmet need for postprandial glycemic control in patients with type 2 diabetes 
      mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia 
      Pacific, the United States, and Latin America. METHODS: Different levels of 
      evidence were used as available for each country/region, with data extracted from 
      seven randomized controlled trials (RCTs), three clinical trial registries 
      (CTRs), and three electronic medical record (EMR) databases. Glycemic status was 
      categorized as "well controlled" (glycated hemoglobin [HbA(1c) ] at target 
      [<7%]), "residual hyperglycemia" (fasting plasma glucose [FPG] but not HbA(1c) at 
      target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country-specific 
      recommendations]), or "uncontrolled" (both FPG and HbA(1c) above target). 
      Predictor factors were identified from the RCT data set using logistic regression 
      analysis. RESULTS: RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% 
      to 38.1% of patients with T2DM had well-controlled glycemia, residual 
      hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective 
      ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR 
      databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant 
      predictor factors of residual hyperglycemia identified from RCT data included 
      high baseline HbA(1c) (all countries/regions except Brazil), high baseline FPG 
      (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex 
      (Europe/Latin America). CONCLUSIONS: Irrespective of intrinsic differences 
      between data sources, 24% to 54% of patients with T2DM globally had residual 
      hyperglycemia with HbA(1c) not at target, despite achieving FPG control, 
      indicating a significant unmet need for postprandial glycemic control.
CI  - (c) 2016 The Authors. Diabetes/Metabolism Research and Reviews published by John 
      Wiley & Sons Ltd.
FAU - Raccah, Denis
AU  - Raccah D
AD  - Department of Diabetology, University Hospital Sainte-Marguerite, Marseille, 
      France.
FAU - Chou, Engels
AU  - Chou E
AD  - Sanofi R&D, Bridgewater, NJ, USA.
FAU - Colagiuri, Stephen
AU  - Colagiuri S
AD  - Boden Institute, University of Sydney, Camperdown, NSW, Australia.
FAU - Gaal, Zsolt
AU  - Gaal Z
AD  - Department of Medicine, Andras Josa Teaching Hospital, Nyiregyhaza, Hungary.
FAU - Lavalle, Fernando
AU  - Lavalle F
AD  - Servicio de Endocrinologia, Facultad de Medicina UANL, Hospital Universitario, 
      Monterrey, NL, Mexico.
FAU - Mkrtumyan, Ashot
AU  - Mkrtumyan A
AD  - Moscow State Medical and Stomatological University named after Evdokimov, Moscow, 
      Russian Federation.
FAU - Nikonova, Elena
AU  - Nikonova E
AD  - Sanofi Global Medical Affairs, Bridgewater, NJ, USA.
FAU - Tentolouris, Nikolaos
AU  - Tentolouris N
AD  - University of Athens Medical School, Athens, Greece.
FAU - Vidal, Josep
AU  - Vidal J
AD  - Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain.
FAU - Davies, Melanie
AU  - Davies M
AD  - Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161013
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Biomarkers/analysis
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Fasting/physiology
MH  - Global Health
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - *Needs Assessment
MH  - Prognosis
PMC - PMC5347910
OTO - NOTNLM
OT  - fasting plasma glucose
OT  - glycemic control
OT  - insulin therapy
OT  - postprandial glucose
OT  - residual hyperglycemia
OT  - type 2 diabetes mellitus
EDAT- 2016/09/09 06:00
MHDA- 2017/09/28 06:00
PMCR- 2017/03/13
CRDT- 2016/09/09 06:00
PHST- 2015/10/23 00:00 [received]
PHST- 2016/05/13 00:00 [revised]
PHST- 2016/09/04 00:00 [accepted]
PHST- 2016/09/09 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/09/09 06:00 [entrez]
PHST- 2017/03/13 00:00 [pmc-release]
AID - DMRR2858 [pii]
AID - 10.1002/dmrr.2858 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2017 Mar;33(3):e2858. doi: 10.1002/dmrr.2858. Epub 2016 
      Oct 13.